CTLs directed against HER2 specifically cross-react with HER3 and HER4.

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• The human epidermal growth factor receptor 2 (HER2) is a target in breast cancer immunotherapy.
• Successful T cell-based therapies require T cells that recognize HER2-expressing tumor cells.

Purpose of the Study:

• To generate and characterize HER2-specific cytotoxic T lymphocytes (CTLs).
• To investigate the potential for cross-reactivity with related HER family members for broader therapeutic targeting.

Main Methods:

• Generation of human cytotoxic T cell clones against the HER2(369-377) epitope presented by HLA-A*0201.
• Assessment of tumor cell lysis by HER2-reactive CTLs.
• Evaluation of tumor cell susceptibility to CTL-mediated lysis after IFN-gamma treatment.
• Analysis of T cell cross-reactivity with HER3 and HER4 peptides.

Main Results:

• HER2-reactive CTLs were generated and demonstrated tumoricidal activity.
• IFN-gamma treatment enhanced tumor cell susceptibility to CTL lysis by up-regulating antigen-presenting machinery.
• Some HER2-reactive T cells cross-reacted with HER3(356-364) and HER4(361-369) epitopes.
• These cross-reacting T cells contributed to the lysis of tumor cells expressing HER3 and/or HER4.

Conclusions:

• HER2-specific CTLs can be generated for breast cancer immunotherapy.
• Tumor cells' antigen-presenting capacity influences CTL efficacy.
• Cross-reactivity of T cells against HER2, HER3, and HER4 offers a strategy for "double" or "triple" targeting in T cell-based therapies.
• This multi-targeting approach holds promise for advancing T cell-based cancer treatments.